Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of bevacizumab-based therapy for metastatic non-squamous NSCLC with untreated asymptomatic brain metastases
2008-006504-33Phase 2Completed
- Sponsor
- Roche
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) and brain metastases (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Jan 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on 2008-006504-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006504-33.